Why Did Peptide Sciences Close Down?

What Happened

On March 6, 2026, at approximately 2:00 PM Eastern, peptidesciences.com went offline. The site was replaced with a single statement: the company had “voluntarily” shut down operations and discontinued the sale of all research products.

No prior warning. No refund process. No mention of outstanding orders. No explanation beyond one carefully chosen word — voluntarily.

Peptide Sciences was the largest grey-market research peptide vendor in the United States. Grips Intelligence data shows the company generated $7.4 million in monthly online sales in December 2025, with over one million website sessions per month. They had operated for over a decade, built one of the most recognized brands in the space, and — per PeptideExaminer’s own assessment — earned the highest vendor rating (B+) in our directory.

And then they were gone.

Three Forces Converged

No single event killed Peptide Sciences. Three independent forces converged to make continued operation untenable.

1. Federal Enforcement Escalation

The regulatory trajectory from 2023 to 2026 was unmistakable and accelerating:

September 2023: FDA places 19 peptides in Category 2, prohibiting compounding. This didn’t directly affect grey-market “research” vendors, but it signaled a new enforcement posture.

December 2024: FDA issues warning letters to four research peptide vendors simultaneously — Prime Peptides, SwissChems, Xcel Peptides, and Summit Research. The letters explicitly cited the Intended Use Doctrine: “research use only” disclaimers are a “ruse” when marketing, dosing guidance, and customer communications indicate human use intent.

January 2025: ITC issues cease and desist orders against multiple vendors (Strate Labs, Arctic Peptides, Triggered Brand) and a General Exclusion Order blocking all tirzepatide imports.

June 2025: FDA raids Amino Asylum’s warehouse, shutting down the operation overnight.

September 2025: FDA issues 50+ warning letters to GLP-1 compounders in a single month. DOJ involvement confirmed.

Early 2026: SAFE Drugs Act introduced, which would make the “research use only” model explicitly illegal by statute rather than just by regulatory interpretation.

Peptide Sciences was never directly targeted with a warning letter. But the pattern was clear: vendors were being picked off one by one, escalating from warning letters to civil enforcement to criminal prosecution. The question wasn’t whether the enforcement wave would reach them — it was when.

2. Big Pharma Litigation

Eli Lilly’s ITC campaign against tirzepatide importers created a powerful new enforcement mechanism that Peptide Sciences couldn’t ignore. The ITC General Exclusion Order covers all tirzepatide imports — not just named respondents. It’s enforced by US Customs at ports of entry, and violations carry penalties up to $100,000 per day.

Novo Nordisk was developing parallel strategies for semaglutide. With branded semaglutide generating billions in annual revenue, pharmaceutical companies had both the financial incentive and the legal resources to pursue grey-market vendors indefinitely.

For Peptide Sciences — which sold both semaglutide and tirzepatide alongside its non-GLP-1 catalog — the litigation risk was existential.

3. Quality Failures Exposed by Finnrick

Finnrick Analytics tested 123 samples of Peptide Sciences products across 10 peptides. The results told a story the company probably didn’t want told:

Products that passed well: Ipamorelin (A rating, 9.2/10 average across 9 tests), PT-141 (A rating), BPC-157 (A rating, 7.8/10 average).

Products that failed badly: CJC-1295 (E rating, 4.3/10 across 10 tests), Tesamorelin (E rating), and most damning — retatrutide received a failing E rating across 37 samples tested between December 2024 and March 2026, with counterfeit products flagged among November 2025 samples.

A customer buying BPC-157 was getting quality product. The same customer buying CJC-1295 was getting substandard material. Anyone buying retatrutide was playing roulette with counterfeits.

This pattern — strong performance on established, simpler peptides but failure on newer, more complex compounds — suggests supply chain vulnerability. When demand surges for high-value products like retatrutide, counterfeit suppliers enter the pipeline. Without pharmaceutical-grade quality controls, even well-intentioned vendors can’t reliably detect the fakes.

What the Market Says

Dr. Steven Murphy called the closure “something quietly seismic.” Jay Campbell of BioLongevity Labs was more direct: “The federal government — DOJ, FBI, and FDA — has decided that RUO peptide manufacturing and distribution can no longer sell, manufacture, or distribute injectable peptides. Anything injectable is now toast.”

This tracks with the broader pattern. At least eight research peptide vendors shut down between 2025 and early 2026. Two vendor operations (All American Peptide, Tailor Made Compounding) resulted in federal criminal convictions with combined forfeitures exceeding $4.7 million.

PeptideExaminer’s Assessment

We rated Peptide Sciences B+ — the highest grade in our vendor directory. We stand by that assessment based on the data available at the time it was issued. But the Finnrick results, which became available after our initial rating, and the voluntary shutdown itself, confirm what we’ve always said: even the best grey-market vendor operates without the quality controls that regulated pharmaceutical manufacturing provides.

B+ in the grey market was never equivalent to pharmaceutical-grade. The shutdown makes that distinction permanent.

What Former Customers Should Know

Immediate steps: Do not buy from any site claiming to be Peptide Sciences. Finnrick confirmed that any site still operating under this name is fraudulent. If you have unfulfilled orders, initiate a chargeback with your bank immediately — credit card chargebacks typically have a 60-120 day window.

If you have remaining product: Lyophilized (powder) peptides stored at -20°C retain potency for months. Reconstituted peptides in the refrigerator should be used within 30 days. The Finnrick data can help you assess the likely quality of what you have — BPC-157 and ipamorelin were strong; CJC-1295 and retatrutide were not.

For transition to legal channels: When the FDA formally reclassifies Category 2 peptides to Category 1 (still pending as of late March 2026), licensed compounding pharmacies will be the safest source. This requires a physician prescription. Telehealth platforms including Hims & Hers are actively building peptide programs. See our vendor ratings for current options.

The Larger Pattern

The grey-market model for injectable peptides is ending. Not because peptides are dangerous — many have genuinely interesting research profiles. Not because demand is declining — it’s surging. But because the regulatory, legal, and enforcement framework that tolerated “research use only” sales has collapsed.

The future of peptide access is through regulated channels: physician prescriptions, licensed compounding pharmacies, and eventually pharmaceutical products from companies like Hims & Hers. That transition is painful for people who relied on the grey market for affordable access. But it’s also the transition that leads to quality controls, adverse event monitoring, and the kind of accountability that an unregulated market can never provide.

Peptide Sciences — the best the grey market had to offer — chose to exit before that exit was forced. The vendors still operating should take note.

PeptideExaminer — We don’t sell peptides. We tell you the truth about them.